<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54254">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399839</url>
  </required_header>
  <id_info>
    <org_study_id>AEGR- 733-027</org_study_id>
    <nct_id>NCT02399839</nct_id>
  </id_info>
  <brief_title>Global Lomitapide Pregnancy Exposure Registry</brief_title>
  <official_title>Global Lomitapide Pregnancy Exposure Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aegerion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aegerion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the outcomes of pregnancy in women treated with lomitapide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the outcomes of pregnancy in women treated with lomitapide at any time within 30
      days prior to first day of Last Menstrual Period (LMP) or during pregnancy. The outcomes of
      primary interest are major congenital anomalies.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">March 2028</completion_date>
  <primary_completion_date type="Anticipated">March 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Pregnancy</measure>
    <time_frame>2 Years</time_frame>
    <description>To evaluate the outcomes of pregnancy in women treated with lomitapide at any time within 30 days prior to first day of Last Menstrual Period (LMP) or during pregnancy.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pregnancy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomitapide</intervention_name>
    <description>As prescribed by Physician.</description>
    <other_name>Juxtapid</other_name>
    <other_name>Lojuxta</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant Females
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant females exposed to lomitapide at any time within 30 days prior to first day
             of the LMP or during pregnancy.

        Exclusion Criteria:

          -  Patients who are unable or unwilling to provide written informed consent or assent
             are not eligible to participate in the PER.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Phillips, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aegerion Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>January 13, 2016</lastchanged_date>
  <firstreceived_date>March 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
